http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107267515-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107267515-B |
| titleOfInvention | CRISPR/Cas9 targeted knockout human CNE10 gene and specific gRNA thereof |
| abstract | The invention belongs to the technical field of molecular biology and biomedicine, and particularly relates to application of a gRNA sequence based on a CRISPR/Cas9 system and a combination thereof in knocking out a conserved non-coding sequence CNE10 of a human dwarf homologous gene (SHOX) and research in the process of regulating and controlling the occurrence of a SHOX gene-related disease by the CNE 10. According to the design principle of CRISPR/Cas9, 2 most effective targets are respectively designed on the upstream and downstream of a CNE10 genome, a sequence table of the targets is shown as SEQ ID NO.1-4, then the targets are respectively constructed on a px458 vector, and 1 guide RNA (gRNA) is obtained by respectively screening the upstream and downstream of a CNE10 genome. The 2 gRNA mediated CRISPR/Cas9 system is utilized in human osteosarcoma cells (U2 OS), the SHOX conserved non-coding sequence CNE10 can be effectively knocked out, and the system is simple and convenient to operate, high in knocking-out efficiency and suitable for cell models for researching multiple functions of genes. The gRNA related to the invention is expected to be popularized and applied in the treatment of CNE10 regulation and control SHOX gene related diseases (chondrocyte dysplasia, autism, Rett syndrome and pancreatic hypoplasia). |
| priorityDate | 2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.